Efforts to build up local, sustainable drug manufacturing capacity in low- and middle-income countries (LMICs) will not work unless “intellectual property barriers” such as patents and data protection are addressed, according to a group of NGOs, health activists and medical charities including Health Action International, Unitaid and Public Citizen.
“Building a bridge to a well distributed, capacitated and sustainable manufacturing capacity in LMIC regions will be essential to their...





